V Blanchette
Overview
Explore the profile of V Blanchette including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
102
Citations
880
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Blanchette V, Brousseau-Foley M
Rev Med Interne
. 2021 Jan;
42(3):193-201.
PMID: 33451819
Infection is one of the most common complications of diabetic foot ulceration resulting in lower extremity amputations and early mortality in this population. Several factors influence the course of diabetic...
2.
Gibson T, Beeput S, Gaspard J, George C, Gibson D, Jackson N, et al.
Pediatr Blood Cancer
. 2018 Aug;
65(12):e27298.
PMID: 30094928
Background: English-speaking Caribbean (ESC) childhood cancer outcomes are unknown. Procedure: Through the SickKids-Caribbean Initiative (SCI), we established a multicenter childhood cancer database across seven centers in six ESC countries. Data...
3.
Hermans C, Mahlangu J, Booth J, Schutz H, Santagostino E, Young G, et al.
Haemophilia
. 2018 May;
24(3):376-384.
PMID: 29732708
Introduction: Currently, no universally accepted definition of extended half-life (EHL) recombinant FVIII (rFVIII) exists. Identifying the minimum half-life extension ratio required for a reduction in dosing frequency compared with standard...
4.
Mahlangu J, Young G, Hermans C, Blanchette V, Berntorp E, Santagostino E
Haemophilia
. 2018 Apr;
24(3):348-358.
PMID: 29633467
Introduction: Recent haemophilia treatment advances include new recombinant FVIII (rFVIII) products with improved pharmacokinetic (PK) properties that aim to reduce the burden of prophylaxis. These treatments are commonly referred to...
5.
Timmer M, Gouw S, Feldman B, Zwagemaker A, de Kleijn P, Pisters M, et al.
Haemophilia
. 2017 Nov;
24(2):e33-e49.
PMID: 29178149
Introduction: Monitoring clinical outcome in persons with haemophilia (PWH) is essential in order to provide optimal treatment for individual patients and compare effectiveness of treatment strategies. Experience with measurement of...
6.
Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E
J Thromb Haemost
. 2017 Nov;
15(12):2461-2465.
PMID: 29119666
No abstract available.
7.
Carneiro J, Blanchette V, Ozelo M, Antunes S, Villaca P, Young N, et al.
Haemophilia
. 2017 Apr;
23(5):682-688.
PMID: 28440005
Introduction: Although the regular replacement of clotting factor concentrates (prophylaxis) has been well established as the standard of care for severe haemophilia, the high cost of factor concentrates has limited...
8.
Limperg P, Terwee C, Young N, Price V, Gouw S, Peters M, et al.
Haemophilia
. 2017 Apr;
23(4):497-510.
PMID: 28429867
Background: The evaluation of health related quality of life (HRQOL) is essential for a full assessment of the influence of an illness on patients' lives. The aim of this paper...
9.
Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, et al.
Haemophilia
. 2017 Mar;
23(3):e170-e179.
PMID: 28345268
Background: Prophylactic replacement with factor concentrate is the optimal treatment for persons with severe haemophilia to avoid or minimize bleeding. This ultimately prevents or reduces joint disease and improves life...
10.
Fischer K, Poonnoose P, Dunn A, Babyn P, Manco-Johnson M, David J, et al.
Haemophilia
. 2016 Sep;
23(1):11-24.
PMID: 27633342
Introduction: The implementation of early long-term, regular clotting factor concentrate (CFC) replacement therapy ('prophylaxis') has made it possible to offer boys with haemophilia a near normal life. Many different regimens...